Bristol-Myers Squibb (BMY) posted early gains Monday and climbed for the bulk of the afternoon. The stock finished higher by $0.59 at $25.05.
Bristol-Myers Squibb has been on an upward trend since early November and closed Monday at a new high for the year. The company announced after the close Friday that it received FDA approval for the supplemental New Drug Application for ABILIFY, for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years.
For comments and feedback: editorial@rttnews.com